Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences (NASDAQ: ANIX) announced completion of the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine from Cleveland Clinic and is now the trial sponsor for future development.
Enrollment was completed in Phase 1 with encouraging immune response and safety data, and Anixa plans to advance the vaccine into a Phase 2 clinical trial using multiple clinical sites, including Cleveland Clinic. The vaccine targets α-lactalbumin, a lactation-associated protein re-expressed in many breast cancers. Phase 1 findings were presented on December 11, 2025 at the San Antonio Breast Cancer Symposium.
Anixa Biosciences (NASDAQ: ANIX) announced final Phase 1 data for its investigational α-lactalbumin (aLA) breast cancer vaccine presented at SABCS on Dec 11, 2025. The trial enrolled 35 participants across three cohorts and met all major primary endpoints. The vaccine was safe and well tolerated at the maximum tolerated dose (MTD), eliciting protocol-defined immune responses in 74% of participants. Combination dosing with pembrolizumab (Keytruda) generated antigen-specific T cell responses with no major additional side effects. Results support advancing to a planned Phase 2 neoadjuvant combination study; participants will be followed for five years. Data were collected in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will speak in the Water Tower Research Fireside Chat on Monday, December 15, 2025 at 1:00 PM ET.
The discussion will cover the final data from Anixa's Phase 1 breast cancer vaccine trial (to be presented December 11, 2025 at the San Antonio Breast Cancer Symposium), the implications of the retired protein strategy for cancer vaccines, and next steps for vaccine development. The event is open to investors and registration is available through Water Tower Research.
Anixa Biosciences (NASDAQ: ANIX) announced that final results from its Phase 1 alpha-lactalbumin (aLA) breast cancer vaccine trial will be presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025 (5:00–6:30 PM CST, Poster PS4-06-19, Abstract 765).
The trial was conducted at Cleveland Clinic and funded by a U.S. Department of Defense grant. Comprehensive blood and tissue analyses are underway and a full report will be submitted to the Department of Defense and the U.S. Food and Drug Administration to inform Phase 2 planning.
Anixa (NASDAQ: ANIX) announced that the WHO INN Expert Committee approved "liraltagene autoleucel" as the International Nonproprietary Name for its FSHR-targeted CAR-T therapy for recurrent ovarian cancer on Nov. 17, 2025. The company said the INN enables a universally recognized, conflict-free drug name and that it will transition communications to liraltagene autoleucel (lira-cel). Anixa reported its ongoing Phase 1 trial is being conducted with Moffitt Cancer Center and expects to commence the 5th dose cohort in the coming weeks. Company leadership and a co-inventor at Duke highlighted the INN approval as a key step toward potential future commercialization.
Anixa Biosciences (NASDAQ: ANIX) said the USPTO will issue U.S. Patent No. 12,472,205 on November 18, 2025, covering methods to induce immune responses to α-lactalbumin for a breast cancer vaccine.
The patent is exclusively licensed from Cleveland Clinic and, together with related patents, is described as extending foundational IP protection for the vaccine program into the mid-2040s. The company calls the program a preventive immunotherapy that targets a protein usually limited to lactation and also expressed in certain breast cancers.
The announcement notes the vaccine remains investigational and that no FDA-approved breast cancer vaccine currently exists, while citing U.S. projections of breast cancer incidence and mortality for context.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman & CEO Dr. Amit Kumar will participate in a Water Tower Research Fireside Chat on Tuesday, November 11, 2025 at 11:00 AM PT.
The live discussion, hosted by Robert Sassoon, will cover an overview of the company, current clinical programs, and the breast cancer vaccine Phase 1 clinical trial status. The event is open to all investors with registration via Water Tower Research.
Anixa Biosciences (NASDAQ: ANIX) executed a data transfer agreement (DTA) with Cleveland Clinic on Nov. 5, 2025 to move Phase 1 breast cancer vaccine clinical data and support transfer of the IND sponsorship to Anixa.
The company says Phase 1 enrollment is complete and showed encouraging immune response signals; Anixa plans to assume full IND sponsorship and advance the vaccine into a Phase 2 trial. Final Phase 1 data will be presented at the San Antonio Breast Cancer Symposium on Dec. 11, 2025.
Anixa Biosciences (NASDAQ: ANIX) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 at the Marriott Marquis Hotel in New York City. Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings.
The conference features over 60 selected companies across multiple sectors and expects more than 500 institutional and high-net-worth investors. The event includes main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions. A video recording of Anixa's presentation will be available after the conference on the company website.
Anixa Biosciences (NASDAQ: ANIX) announced that the Chinese National Intellectual Property Administration issued Patent No. ZL2020800215666, covering key aspects of its breast cancer vaccine technology and extending IP protection in China into the 2040s.
The vaccine, invented at Cleveland Clinic and exclusively licensed to Anixa, targets human α-lactalbumin to prevent and treat certain breast cancers. Anixa said this patent strengthens its global patent estate and supports future international development and commercialization. A Phase 1 trial has been completed and full results will be presented on Dec 11, 2025 at the San Antonio Breast Cancer Symposium.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
